Nkarta Inc. logo

Nkarta Inc. (NKTX)

Market Closed
11 Jul, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
1. 83
+0.03
+1.67%
$
124.18M Market Cap
- P/E Ratio
0% Div Yield
714,500 Volume
-2.1 Eps
$ 1.8
Previous Close
Day Range
1.74 1.83
Year Range
1.31 8.23
Want to track NKTX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 25 days
Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors

Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors

Senior R&D leader brings extensive expertise in immunology, clinical development and translational science Senior R&D leader brings extensive expertise in immunology, clinical development and translational science

Globenewswire | 1 year ago
Nkarta: Finally An Attractive Valuation

Nkarta: Finally An Attractive Valuation

Nkarta Inc. is using natural killer cells engineered with CARs and membrane-bound IL-15 to target autoimmune diseases and oncology. The company's off-the-shelf availability and superior safety profile make it an attractive option for patients, providers, and payers. Nkarta is targeting large markets, such as lupus nephritis and non-Hodgkin lymphoma, with the potential to produce blockbuster therapies.

Seekingalpha | 1 year ago